open access

Vol 14, No 2 (2021)
Review paper
Published online: 2021-12-31
Get Citation

Immunosuppressive therapy following kidney transplantation in elderly recipients

Magdalena Jankowska1
DOI: 10.5603/RDTF.2021.0008
·
Renal Disease and Transplantation Forum 2021;14(2):58-65.
Affiliations
  1. Department of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk

open access

Vol 14, No 2 (2021)
Review Articles
Published online: 2021-12-31

Abstract

The benefits of kidney transplantation warrant the treatment being offered to a growing population of
elderly patients with kidney failures. Kidney transplantation in recipients older than 65 is associated
with some challenges due to the less optimal function of organs from older donors, age-related differences in immune response, pharmacokinetics, and pharmacodynamics of immunosuppressive drugs, comorbidities, and adverse events. Few clinical trials have evaluated the safety of modified immunosuppressive therapies in the elderly. Current recommendations are based on the immunological risk; however, further studies are needed to investigate immunosuppressive agents’ safety, efficacy, and target levels in elderly kidney transplant recipients.

Abstract

The benefits of kidney transplantation warrant the treatment being offered to a growing population of
elderly patients with kidney failures. Kidney transplantation in recipients older than 65 is associated
with some challenges due to the less optimal function of organs from older donors, age-related differences in immune response, pharmacokinetics, and pharmacodynamics of immunosuppressive drugs, comorbidities, and adverse events. Few clinical trials have evaluated the safety of modified immunosuppressive therapies in the elderly. Current recommendations are based on the immunological risk; however, further studies are needed to investigate immunosuppressive agents’ safety, efficacy, and target levels in elderly kidney transplant recipients.

Get Citation

Keywords

kidney, transplantation, elderly

About this article
Title

Immunosuppressive therapy following kidney transplantation in elderly recipients

Journal

Renal Disease and Transplantation Forum

Issue

Vol 14, No 2 (2021)

Article type

Review paper

Pages

58-65

Published online

2021-12-31

DOI

10.5603/RDTF.2021.0008

Bibliographic record

Renal Disease and Transplantation Forum 2021;14(2):58-65.

Keywords

kidney
transplantation
elderly

Authors

Magdalena Jankowska

References (59)
  1. Tonelli M, Wiebe N, Knoll G, et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant. 2011; 11(10): 2093–2109.
  2. Heldal K, Hartmann A, Grootendorst DC, et al. Benefit of kidney transplantation beyond 70 years of age. Nephrol Dial Transplant. 2010; 25(5): 1680–1687.
  3. de Fijter JW. Counselling the elderly between hope and reality. Nephrol Dial Transplant. 2011; 26(7): 2079–2081.
  4. Heldal K, Hartmann A, Lønning K, et al. Should patients older than 65 years be offered a second kidney transplant? BMC Nephrol. 2017; 18(1): 13.
  5. Pippias M, Stel VS, Kramer A, et al. Access to kidney transplantation in European adults aged 75-84 years and related outcomes: an analysis of the European Renal Association-European Dialysis and Transplant Association Registry. Transpl Int. 2018; 31(5): 540–553.
  6. Segall L, Nistor I, Pascual J, et al. Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease. Transplantation. 2016; 100(10): e55–e65.
  7. Peters-Sengers H, Berger SP, Heemskerk MBA, et al. Stretching the Limits of Renal Transplantation in Elderly Recipients of Grafts from Elderly Deceased Donors. J Am Soc Nephrol. 2017; 28(2): 621–631.
  8. Ojo AO, Hanson JA, Meier-Kriesche HU, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001; 12(3): 589–597.
  9. Pippias M, Jager KJ, Caskey F, et al. Kidney transplant outcomes from older deceased donors: a paired kidney analysis by the European Renal Association-European Dialysis and Transplant Association Registry. Transpl Int. 2018; 31(7): 708–719.
  10. Pippias M, Jager KJ, Åsberg A, et al. Young deceased donor kidneys show a survival benefit over older donor kidneys in transplant recipients aged 20-50 years: a study by the ERA-EDTA Registry. Nephrol Dial Transplant. 2020; 35(3): 534–543.
  11. O'Sullivan ED, Hughes J, Ferenbach DA. Renal Aging: Causes and Consequences. J Am Soc Nephrol. 2017; 28(2): 407–420.
  12. Rule AD, Amer H, Cornell LD, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Intern Med. 2010; 152(9): 561–567.
  13. de Fijter JW. The impact of age on rejection in kidney transplantation. Drugs Aging. 2005; 22(5): 433–449.
  14. Klinger M, Banasik M. Immunological characteristics of the elderly allograft recipient. Transplant Rev (Orlando). 2015; 29(4): 219–223.
  15. Tylutka A, Zembroń-Łacny A. Immunological aging and clinical consequences. Postępy Higieny i Medycyny Doświadczalnej. 2020; 74: 260–271.
  16. Jankowska M, Marszałł M, Dębska-Ślizień A, et al. Vitamin B6 and the immunity in kidney transplant recipients. J Ren Nutr. 2013; 23(1): 57–64.
  17. Krenzien F, ElKhal A, Quante M, et al. A Rationale for Age-Adapted Immunosuppression in Organ Transplantation. Transplantation. 2015; 99(11): 2258–2268.
  18. Meier-Kriesche HU, Ojo AO, Hanson JA, et al. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int. 2001; 59(4): 1539–1543.
  19. Meier-Kriesche HU, Ojo A, Hanson J, et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation. 2000; 69(5): 885–889.
  20. Meier-Kriesche HU, Friedman G, Jacobs M, et al. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. Transplantation. 1999; 68(10): 1496–1502.
  21. Trzonkowski P, Debska-Slizień A, Jankowska M, et al. Immunosenescence increases the rate of acceptance of kidney allotransplants in elderly recipients through exhaustion of CD4+ T-cells. Mech Ageing Dev. 2010; 131(2): 96–104.
  22. Shi YY, Hesselink DA, van Gelder T. Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients. Transplant Rev (Orlando). 2015; 29(4): 224–230.
  23. Cossart AR, Isbel NM, Scuderi C, et al. Pharmacokinetic and Pharmacodynamic Considerations in Relation to Calcineurin Usage in Elderly Kidney Transplant Recipients. Front Pharmacol. 2021; 12: 635165.
  24. Shi S, Mörike K, Klotz U. The clinical implications of ageing for rational drug therapy. Eur J Clin Pharmacol. 2008; 64(2): 183–199.
  25. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004; 57(1): 6–14.
  26. Falck P, Asberg A, Byberg KT, et al. Reduced elimination of cyclosporine A in elderly (>65 years) kidney transplant recipients. Transplantation. 2008; 86(10): 1379–1383.
  27. Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12(12): 3326–3336.
  28. David-Neto E, Romano P, Kamada Triboni AH, et al. Longitudinal Pharmacokinetics of Tacrolimus in Elderly Compared With Younger Recipients in the First 6 Months After Renal Transplantation. Transplantation. 2017; 101(6): 1365–1372.
  29. Thölking G, Fortmann C, Koch R, et al. The tacrolimus metabolism rate influences renal function after kidney transplantation. PLoS One. 2014; 9(10): e111128.
  30. Oberbauer R, Bestard O, Furian L, et al. Optimization of tacrolimus in kidney transplantation: New pharmacokinetic perspectives. Transplant Rev (Orlando). 2020; 34(2): 100531.
  31. January SE, Hagopian JC, Nesselhauf NM, et al. Clinical Experience with Extended-Release Tacrolimus in Older Adult Kidney Transplant Recipients: A Retrospective Cohort Study. Drugs Aging. 2021; 38(5): 397–406.
  32. Sánchez Fr, Ruiz JC, Franco A, et al. Effectiveness and safety of the conversion to MeltDose. Clin Transplant. 2020; 34(1): e13767.
  33. Tang JT, de Winter BC, Hesselink DA, et al. The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. Br J Clin Pharmacol. 2017; 83(4): 812–822.
  34. Miura M, Satoh S, Kagaya H, et al. No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation. Eur J Clin Pharmacol. 2009; 65(10): 1047–1053.
  35. Staatz CE, Tett SE. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update. Arch Toxicol. 2014; 88(7): 1351–1389.
  36. Dansirikul C, Morris RG, Tett SE, et al. A Bayesian approach for population pharmacokinetic modelling of sirolimus. Br J Clin Pharmacol. 2006; 62(4): 420–434.
  37. Shihab F, Christians U, Smith L, et al. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol. 2014; 31(1): 22–32.
  38. Shen J, Townsend R, You X, et al. Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. Clin Drug Investig. 2014; 34(2): 117–126.
  39. Zhou Z, Shen J, Hong Y, et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther. 2012; 92(2): 251–257.
  40. Fialová D, Laffon B, Marinković V, et al. EUROAGEISM H2020 project and WG1b group “Healthy clinical strategies for healthy aging” of the EU COST Action IS 1402. Medication use in older patients and age-blind approach: narrative literature review (insufficient evidence on the efficacy and safety of drugs in older age, frequent use of PIMs and polypharmacy, and underuse of highly beneficial nonpharmacological strategies). Eur J Clin Pharmacol. 2019; 75(4): 451–466.
  41. Srinivas TR, Meier-Kriesche HU. Minimizing immunosuppression, an alternative approach to reducing side effects: objectives and interim result. Clin J Am Soc Nephrol. 2008; 3 Suppl 2: S101–S116.
  42. Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive? Drugs Aging. 2001; 18(10): 751–759.
  43. Meier-Kriesche HU, Srinivas TR, Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplantation Proceedings. 2001; 33(7-8): 3425–3426.
  44. Meier-Kriesche HU, Kaplan B. Death after graft loss: a novel endpoint for renal tranplantation. Transplantation Proceedings. 2001; 33(7-8): 3405–3406.
  45. Andrés A, Budde K, Clavien PA, et al. SENIOR Study Team. A randomized trial comparing renal function in older kidney transplant patients following delayed versus immediate tacrolimus administration. Transplantation. 2009; 88(9): 1101–1108.
  46. Meier M, Bode W, Nitschke M. High rejection rates with low dose immunosuppression in old for old kidney transplantation. Transplantationsmedizin: Organ der Deutschen Transplantationsgesellschaft. 2011; 23(2): 118–126.
  47. Badowski M, Gurk-Turner C, Cangro C, et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant. 2009; 23(6): 930–937.
  48. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014; 6(268): 268ra179.
  49. Diekmann F, Campistol JM, Saval N, et al. Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation. Transplantation. 2007; 84(3): 429–432.
  50. Furian L, Baldan N, Margani G, et al. Calcineurin inhibitor-free immunosuppression in dual kidney transplantation from elderly donors. Clin Transplant. 2007; 21(1): 57–62.
  51. Cruzado JM, Bestard O, Riera L, et al. Immunosuppression for dual kidney transplantation with marginal organs: the old is better yet. Am J Transplant. 2007; 7(3): 639–644.
  52. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10(3): 535–546.
  53. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10(3): 547–557.
  54. Kumar J, Reccia I, Virdis F, et al. Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review. World J Transplant. 2021; 11(3): 70–86.
  55. Alsheikh R, Gabardi S. Post-Renal Transplantation Outcomes in Elderly Patients Compared to Younger Patients in the Setting of Early Steroid Withdrawal. Prog Transplant. 2018; 28(4): 322–329.
  56. Gill J, Sampaio M, Gill JS, et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol. 2011; 6(5): 1168–1178.
  57. Masset C, Boucquemont J, Garandeau C, et al. DIVAT Consortium. Induction Therapy in Elderly Kidney Transplant Recipients With Low Immunological Risk. Transplantation. 2020; 104(3): 613–622.
  58. Bunnapradist S, Rostaing L, Alloway RR, et al. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Transpl Int. 2016; 29(5): 603–611.
  59. Durlik M, Przybyłowski P. Zalecenia dotyczące leczenia immunosupresyjnego po przeszczepieniu narządów unaczynionych. Warszawa: Fundacja Zjednoczeni dla Transplantacji. ; 2018.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.